Bluebird Bio Cmn (BLUE) 40.22 $BLUE
AWS Morning Technical Breakdown Highlights: bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro
ACCESSWIRE - Mon May 23, 8:18AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro.
BLUE: 40.22 (+0.43), SQNM: 1.12 (-0.03), TSRO: 42.47 (+1.53), NKTR: 15.09 (+0.11)
bluebird bio to Present at Goldman Sachs 37th Annual Healthcare Conference
BusinessWire - Mon May 23, 7:30AM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the Goldman Sachs 37th Annual Healthcare Conference on June 8, 2016 at 8:00 am PT (11:00 am ET). The conference is being held June 7-9, 2016 at the Terranea Resort in Rancho Palos Verdes, Calif.
BLUE: 40.22 (+0.43)
Join Victory Living Programs to Host 6th Annual Black and Blue Dine Around Event at Blue Martini and The Capital Grille in Fort Lauderdale
PR Newswire - Thu May 12, 9:00AM CDT
Victory Living Programs' Annual Black and Blue Dine Around event, held this year on Sunday, June 5, 2016 at 5:30 p.m., offers a unique dining and dancing experience complete with cocktails, dinner and dessert.
BLUE: 40.22 (+0.43)
bluebird bio Presents Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting
BusinessWire - Mon May 09, 7:30AM CDT
bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies for cancer, today announced the presentation of pre-clinical data from its immuno-oncology and hematopoietic stem cell (HSC) gene therapy programs at the American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting, taking place May 4-7, 2016 in Washington, D.C.
BLUE: 40.22 (+0.43)
bluebird bio Reports First Quarter 2016 Financial Results and Recent Operational Progress
BusinessWire - Wed May 04, 3:05PM CDT
--- Ten abstracts accepted for presentation at American Society for Gene and Cell Therapy (ASGCT) Meeting -
BLUE: 40.22 (+0.43)
Forget Bluebird Bio, Inc.: These 3 Stocks Are Better Buys
Cory Renauer, The Motley Fool - Motley Fool - Tue May 03, 7:03AM CDT
Image source: bluebird bio. Against the mosaic of young, clinical-stage, gene-editing, cellular-therapy biotechs, bluebird bio (NASDAQ: BLUE) stands tall, despite its disdain for uppercase consonants. It has produced some amazing results in small...
BLUE: 40.22 (+0.43), BIIB: 234.60 (+1.60), VRTX: 85.22 (-0.06), MRK: 57.04 (+0.79)
Global Gene Therapy Market Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Advantagene, Bluebird Bio, Genethon - Research and Markets
BusinessWire - Tue Apr 26, 10:39AM CDT
Research and Markets has announced the addition of the "Global Gene Therapy Market Forecast to 2020" report to their offering.
BLUE: 40.22 (+0.43)
bluebird bio, Inc. Takes Flight Towards First Approval
Cory Renauer, The Motley Fool - Motley Fool - Thu Apr 21, 8:21AM CDT
Image source: bluebird bio, On Wednesday, April 20, at about 8:30AM, gene editing pioneer bluebird bio (NASDAQ: BLUE) reported interim results from the only study running right now that might earn it an FDA approval. Although it's interim data...
BLUE: 40.22 (+0.43)
bluebird bio to Present Immuno-Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting
BusinessWire - Mon Apr 18, 3:05PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies for cancer, today announced that data from clinical, preclinical, and research and manufacturing programs will be highlighted in ten presentations at the American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting, taking place May 4-7, 2016 in Washington, D.C.
BLUE: 40.22 (+0.43)
Here's Why bluebird bio.'s Stock Tumbled in March
George Budwell, The Motley Fool - Motley Fool - Tue Apr 12, 8:27AM CDT
What: Shares of the clinical-stage biotech bluebird bio shed nearly 16% of their value last month, according to data from S&P Global Market Intelligence . On the bright side, bluebird's poor showing last month seems to be the result of an...
BLUE: 40.22 (+0.43), IBB: 256.56 (+1.77)
[Podcast] Slingshot Insights and Estimize talk Biotech, Markets, and Forcerank
ESTMZ - Fri Apr 08, 10:42AM CDT
In case you missed it, check out the recording of yesterday’s webinar with Slingshot Insights! Leigh Drogen, Founder of Estimize, joins Joe McCann of Slingshot Insights to talk Biotech stocks, the market, and his latest creation ForceRank....
BLUE: 40.22 (+0.43), BIIB: 234.60 (+1.60), ALNY: 56.14 (+0.36), KITE: 51.14 (+0.23), CELG: 99.23 (+2.37)
Why Bluebird Bio Inc. Plunged Today
Brian Feroldi, The Motley Fool - Motley Fool - Wed Mar 23, 8:48PM CDT
Image source: Bluebird Bio. What: Shares of Bluebird Bio , a clinical-stage biotechnology company focused on gene therapy, dropped by more than 11% on Wednesday. So what: There doesn't appear to be any news to justify such a big move, so...
BLUE: 40.22 (+0.43), XBI: 53.30 (+0.11)
Synlogic Appoints an Industry Leader Nick Leschly to Its Board of Directors
BusinessWire - Wed Mar 23, 7:00AM CDT
Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and microbiome platform, today announced the expansion of its Board of Directors with the appointment of Mr. Nick Leschly, CEO of bluebird bio (NASDAQ: BLUE), Inc., as an independent Director.
BLUE: 40.22 (+0.43)
Why bluebird bio Inc Presented a Lower Price Today
Brian Orelli, The Motley Fool - Motley Fool - Tue Mar 08, 3:22PM CST
STEPS OF GENE THERAPY. IMAGE SOURCE: BLUEBIRD BIO. What: bluebird bio was down as much as 12% Tuesday, apparently on no news. The stock just started falling from the open and never really recovered. So what: Let's keep this in perspective....
BLUE: 40.22 (+0.43)
bluebird bio to Present Clinical Data on Lenti-D in CALD in Plenary Session at AAN 2016 Annual Meeting
BusinessWire - Thu Mar 03, 3:39PM CST
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that interim data from the ongoing Phase 2/3 Starbeam Study (ALD-102) for the treatment of cerebral adrenoleukodystrophy (CALD) will be presented in an oral presentation during the Clinical Trials plenary session on April 20, 2016 at the American Academy of Neurology (AAN) 2016 Annual Meeting. The meeting is being held April 15 - 21, 2016 in Vancouver, BC, Canada.
BLUE: 40.22 (+0.43)
Why Celldex Therapeutics, Inc. and bluebird bio, Inc. Jumped Today
Brian Orelli, The Motley Fool - Motley Fool - Tue Mar 01, 3:26PM CST
What: A day after it fell a little over 10%, Celldex Therapeutics is up about 10% in the last hour of trading Tuesday after an analyst initiated coverage with a buy. On the other hand, bluebird bio is up about 10%, for apparently no reason....
BLUE: 40.22 (+0.43), CLDX: 4.45 (-0.01), IBB: 256.56 (+1.77)
Why bluebird bio Inc.'s Stock Dropped 34% in January
Brian Feroldi, The Motley Fool - Motley Fool - Mon Feb 08, 10:22AM CST
What: January was a month to forget for investors in bluebird bio , a clinical-stage biotechnology company focused on gene therapy. The stock shed more than 34% of its value during the month, according to data from S&P Capital IQ . Bluebird...
BLUE: 40.22 (+0.43), BLCM: 12.23 (-0.26)
4 Top-Ranked Biotech Stocks on Sale
Swarup Gupta - Zacks Investment Research - Tue Feb 02, 9:46AM CST
Given the fact that sector fundamentals remain strong and the long-term outlook of biotechs is bright this may be a good time to pick up such stocks on the cheap.
BLUE: 40.22 (+0.43), BIIB: 234.60 (+1.60), INSY: 12.78 (+0.16), GILD: 82.45 (+0.66), UTHR: 103.36 (+1.56), MYL: 45.00 (+0.12), JUNO: 42.62 (-0.04)
AWS Morning Technical Breakdown Highlights: bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro
ACCESSWIRE - Mon May 23, 8:18AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro.
BLUE: 40.22 (+0.43), SQNM: 1.12 (-0.03), TSRO: 42.47 (+1.53), NKTR: 15.09 (+0.11)
bluebird bio to Present at Goldman Sachs 37th Annual Healthcare Conference
BusinessWire - Mon May 23, 7:30AM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the Goldman Sachs 37th Annual Healthcare Conference on June 8, 2016 at 8:00 am PT (11:00 am ET). The conference is being held June 7-9, 2016 at the Terranea Resort in Rancho Palos Verdes, Calif.
BLUE: 40.22 (+0.43)
Join Victory Living Programs to Host 6th Annual Black and Blue Dine Around Event at Blue Martini and The Capital Grille in Fort Lauderdale
PR Newswire - Thu May 12, 9:00AM CDT
Victory Living Programs' Annual Black and Blue Dine Around event, held this year on Sunday, June 5, 2016 at 5:30 p.m., offers a unique dining and dancing experience complete with cocktails, dinner and dessert.
BLUE: 40.22 (+0.43)
bluebird bio Presents Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting
BusinessWire - Mon May 09, 7:30AM CDT
bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies for cancer, today announced the presentation of pre-clinical data from its immuno-oncology and hematopoietic stem cell (HSC) gene therapy programs at the American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting, taking place May 4-7, 2016 in Washington, D.C.
BLUE: 40.22 (+0.43)
bluebird bio Reports First Quarter 2016 Financial Results and Recent Operational Progress
BusinessWire - Wed May 04, 3:05PM CDT
--- Ten abstracts accepted for presentation at American Society for Gene and Cell Therapy (ASGCT) Meeting -
BLUE: 40.22 (+0.43)
Forget Bluebird Bio, Inc.: These 3 Stocks Are Better Buys
Cory Renauer, The Motley Fool - Motley Fool - Tue May 03, 7:03AM CDT
Image source: bluebird bio. Against the mosaic of young, clinical-stage, gene-editing, cellular-therapy biotechs, bluebird bio (NASDAQ: BLUE) stands tall, despite its disdain for uppercase consonants. It has produced some amazing results in small...
BLUE: 40.22 (+0.43), BIIB: 234.60 (+1.60), VRTX: 85.22 (-0.06), MRK: 57.04 (+0.79)
Global Gene Therapy Market Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Advantagene, Bluebird Bio, Genethon - Research and Markets
BusinessWire - Tue Apr 26, 10:39AM CDT
Research and Markets has announced the addition of the "Global Gene Therapy Market Forecast to 2020" report to their offering.
BLUE: 40.22 (+0.43)
bluebird bio, Inc. Takes Flight Towards First Approval
Cory Renauer, The Motley Fool - Motley Fool - Thu Apr 21, 8:21AM CDT
Image source: bluebird bio, On Wednesday, April 20, at about 8:30AM, gene editing pioneer bluebird bio (NASDAQ: BLUE) reported interim results from the only study running right now that might earn it an FDA approval. Although it's interim data...
BLUE: 40.22 (+0.43)
bluebird bio to Present Immuno-Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting
BusinessWire - Mon Apr 18, 3:05PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies for cancer, today announced that data from clinical, preclinical, and research and manufacturing programs will be highlighted in ten presentations at the American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting, taking place May 4-7, 2016 in Washington, D.C.
BLUE: 40.22 (+0.43)
Here's Why bluebird bio.'s Stock Tumbled in March
George Budwell, The Motley Fool - Motley Fool - Tue Apr 12, 8:27AM CDT
What: Shares of the clinical-stage biotech bluebird bio shed nearly 16% of their value last month, according to data from S&P Global Market Intelligence . On the bright side, bluebird's poor showing last month seems to be the result of an...
BLUE: 40.22 (+0.43), IBB: 256.56 (+1.77)
[Podcast] Slingshot Insights and Estimize talk Biotech, Markets, and Forcerank
ESTMZ - Fri Apr 08, 10:42AM CDT
In case you missed it, check out the recording of yesterday’s webinar with Slingshot Insights! Leigh Drogen, Founder of Estimize, joins Joe McCann of Slingshot Insights to talk Biotech stocks, the market, and his latest creation ForceRank....
BLUE: 40.22 (+0.43), BIIB: 234.60 (+1.60), ALNY: 56.14 (+0.36), KITE: 51.14 (+0.23), CELG: 99.23 (+2.37)
Why Bluebird Bio Inc. Plunged Today
Brian Feroldi, The Motley Fool - Motley Fool - Wed Mar 23, 8:48PM CDT
Image source: Bluebird Bio. What: Shares of Bluebird Bio , a clinical-stage biotechnology company focused on gene therapy, dropped by more than 11% on Wednesday. So what: There doesn't appear to be any news to justify such a big move, so...
BLUE: 40.22 (+0.43), XBI: 53.30 (+0.11)
Synlogic Appoints an Industry Leader Nick Leschly to Its Board of Directors
BusinessWire - Wed Mar 23, 7:00AM CDT
Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and microbiome platform, today announced the expansion of its Board of Directors with the appointment of Mr. Nick Leschly, CEO of bluebird bio (NASDAQ: BLUE), Inc., as an independent Director.
BLUE: 40.22 (+0.43)
Why bluebird bio Inc Presented a Lower Price Today
Brian Orelli, The Motley Fool - Motley Fool - Tue Mar 08, 3:22PM CST
STEPS OF GENE THERAPY. IMAGE SOURCE: BLUEBIRD BIO. What: bluebird bio was down as much as 12% Tuesday, apparently on no news. The stock just started falling from the open and never really recovered. So what: Let's keep this in perspective....
BLUE: 40.22 (+0.43)
bluebird bio to Present Clinical Data on Lenti-D in CALD in Plenary Session at AAN 2016 Annual Meeting
BusinessWire - Thu Mar 03, 3:39PM CST
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that interim data from the ongoing Phase 2/3 Starbeam Study (ALD-102) for the treatment of cerebral adrenoleukodystrophy (CALD) will be presented in an oral presentation during the Clinical Trials plenary session on April 20, 2016 at the American Academy of Neurology (AAN) 2016 Annual Meeting. The meeting is being held April 15 - 21, 2016 in Vancouver, BC, Canada.
BLUE: 40.22 (+0.43)
Why Celldex Therapeutics, Inc. and bluebird bio, Inc. Jumped Today
Brian Orelli, The Motley Fool - Motley Fool - Tue Mar 01, 3:26PM CST
What: A day after it fell a little over 10%, Celldex Therapeutics is up about 10% in the last hour of trading Tuesday after an analyst initiated coverage with a buy. On the other hand, bluebird bio is up about 10%, for apparently no reason....
BLUE: 40.22 (+0.43), CLDX: 4.45 (-0.01), IBB: 256.56 (+1.77)
Why bluebird bio Inc.'s Stock Dropped 34% in January
Brian Feroldi, The Motley Fool - Motley Fool - Mon Feb 08, 10:22AM CST
What: January was a month to forget for investors in bluebird bio , a clinical-stage biotechnology company focused on gene therapy. The stock shed more than 34% of its value during the month, according to data from S&P Capital IQ . Bluebird...
BLUE: 40.22 (+0.43), BLCM: 12.23 (-0.26)
4 Top-Ranked Biotech Stocks on Sale
Swarup Gupta - Zacks Investment Research - Tue Feb 02, 9:46AM CST
Given the fact that sector fundamentals remain strong and the long-term outlook of biotechs is bright this may be a good time to pick up such stocks on the cheap.
BLUE: 40.22 (+0.43), BIIB: 234.60 (+1.60), INSY: 12.78 (+0.16), GILD: 82.45 (+0.66), UTHR: 103.36 (+1.56), MYL: 45.00 (+0.12), JUNO: 42.62 (-0.04)
